Related Experiment Video

Updated: Jun 12, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Pneumocystis infection in humans: diagnosis and treatment

Enrique J Calderón1, Sonia Gutiérrez-Rivero, Isabelle Durand-Joly

  • 1Instituto de Biomedicina de Sevilla, and CIBER de Epidemiología y Salud Pública, Servicio de Medicina Interna, Virgen del Rocío University Hospital, Seville, Spain. ecalderon@ibis-sevilla.es

Expert Review of Anti-Infective Therapy
|June 5, 2010
PubMed

Insights

Pneumocystis pneumonia, caused by Pneumocystis jirovecii, affects non-HIV immunocompromised patients, presenting diagnostic challenges. Management remains difficult, with limited treatment alternatives beyond cotrimoxazole.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Pulmonology

Background:

  • Pneumocystis jirovecii is an opportunistic fungus with pulmonary tropism.
  • Pneumocystis pneumonia (PCP) is a severe infection primarily in AIDS patients.
  • Increasing recognition of PCP in non-HIV immunosuppressed individuals due to therapies for malignancies, transplants, and autoimmune diseases.

Purpose of the Study:

  • To highlight the growing incidence and challenges of Pneumocystis pneumonia in non-HIV immunocompromised patients.
  • To discuss the diagnostic difficulties and differing clinical presentations compared to HIV-infected patients.
  • To review current treatment options and management challenges for PCP.

Main Methods:

  • Review of current literature on Pneumocystis jirovecii and Pneumocystis pneumonia.
  • Analysis of clinical presentations and diagnostic approaches.
  • Evaluation of therapeutic strategies and challenges.

Main Results:

  • Pneumocystis pneumonia is increasingly diagnosed in non-HIV immunocompromised individuals.
  • Clinical presentation and diagnosis can be challenging due to non-specific symptoms.
  • Cotrimoxazole is the primary treatment, with limited alternative options.

Conclusions:

  • Pneumocystis pneumonia poses a significant challenge in non-HIV immunosuppressed populations.
  • Early diagnosis and appropriate management are crucial.
  • Further research into alternative treatments is warranted.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...